Macular degeneration: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• VEGF 19
• NRF2 0
• GLP-1 0
• PPAR 0
• AKT 0
• JNK 0
• APOE 0
• PI3K 0
• SIRT1 0
• ALK 1
• AMPK 0
• MAPK 0
• mTOR 0
• GPX4 0
• JAK 0
• NLRP3 0
• TP53 0
• ERK 0
• PCSK9 0
• STAT3 0
• STING 0
• YAP 0
• BCL-2 0
• CTNNB1 0
• CXCR4 0
• HIF-1 0
• IL-6 0
• MMP-9 1
• PDGFR 0
• SGLT2 1
• TNF 0
• IL-17 0
• MDM2 0
• MYC 0
• NOTCH3 0
• PKM2 0
• RPGR 0
• SOD1 0
• TERT 0
• TFEB 0
• TREM2 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NEI · R43

  PRMT5 Inhibitors as a Novel Therapy for Anti-VEGF-Sensitive and -Resistant Neovascular Age-Related Macular Degeneration

  Eqon Pharmaceuticals, Llc· Carmel, United States· US$233,247 awarded in fiscal year 2026· until Aug 2028

• NIH NEI · R01

  Metabolic tuning and signaling in retinal health and disease

  University of Wisconsin-Madison· Madison, United States· US$608,985 awarded in fiscal year 2026· until Aug 2030

• NIH NEI · R21

  Leveraging Ocular B cells to identiry antigen triggers in uveitis

  University of Colorado Denver· Aurora, United States· US$429,000 awarded in fiscal year 2026· until Aug 2028

• NIH NEI · U01

  RURAL Eye Health Study

  Southern California Eye Institute· Los Angeles, United States· US$1,089,223 awarded in fiscal year 2026· until May 2031

• NIH NEI · R01

  Identifying barriers to retinal Muller glial reprogramming

  University of California, San Diego· La Jolla, United States· US$499,606 awarded in fiscal year 2026· until Jun 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Decoding retinal cell communication to counteract vision loss in aging (VisionGuard)

  Aarhus Universitet· Aarhus C, Denmark· EU contribution €263,393· until Apr 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Drusen Reconstitution in an Engineered AMD Model using Retinal Pigment Epithelium (DREAM_RPE)

  Universidade Nova de Lisboa· Lisboa, Portugal· EU contribution €207,183· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Doctoral network on discovering pathomechanisms and novel drug optimization for AMD (PANDORA)

  Eberhard Karls Universitaet Tuebingen· Tuebingen, Germany· EU contribution €4,020,973· until Sept 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Full field optoretinography for elderly eye health (FFORGE)

  Institut National de la Sante Et de la Recherche Medicale· Paris, France· EU contribution €150,000· until Feb 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Lysophagy as a new strategy for neuroprotection in dry AMD (AMD_Prog)

  Universite de Fribourg· Fribourg, Switzerland· EU contribution €307,959· until Aug 2028

10 of 347 running projects, newest first. Listed amounts together: US$182.7m + €21.9m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Organoids 11
• Mendelian Randomization Analysis 26
• CRISPR-Cas Systems 7
• Gene Expression Profiling 16
• Sequence Analysis, RNA 3
• Whole Genome Sequencing 1
• Exome Sequencing 2
• Proteomics 21
• Metabolomics 16
• Mass Spectrometry 11
• Flow Cytometry 8
• Immunohistochemistry 15
• Liquid Biopsy 1
• Magnetic Resonance Imaging 6
• Machine Learning 14
• Deep Learning 31
• Cohort Studies 26
• Genome-Wide Association Study 24

• Metabolomic Signatures of Healthy Dietary Patterns Associated With Lower Risk of Age-Related Macular Degeneration.

  Invest Ophthalmol Vis Sci, Nov 2026

• Multimodal Exploratory Analysis of Persistent Diabetic Macular Edema: Integrating Aqueous Humour Metabolomics, Clinical and OCT Features.

  Diabetes Obes Metab, Sept 2026

• Utilize Metabolomics Molecular Networking to Guide the Discovery of Chemical Entities from Cordyceps militaris Against Blue Light Hazards.

  J Nat Prod, Aug 2026

• Adaptive and degenerative mitochondrial remodeling define distinct redox states in age-related macular degeneration.

  Redox Biol, Aug 2026

• Personalized Dosing System Guided by Cross-Scale Metabolic Imaging Biomarkers in Neovascular Age-Related Macular Degeneration.

  Transl Vis Sci Technol, Jun 2026

• Association of age-related macular degeneration with exposome related metabolomics.

  Metabolomics, May 2026

• Integrated plasma proteomics and metabolomics reveal immunometabolic pathways and predictive signatures for age-related eye diseases.

  Metabolism, Apr 2026

• Integrated transcriptomic and metabolomic analyses reveal distinct energy metabolic signatures and functional properties of RPE cells under two culture conditions.

  Sci Rep, Apr 2026

• Zhujing Pill ameliorates age-related macular degeneration by regulating lipid metabolism, complement activation, and inflammatory responses: an integrated network pharmacology and metabolomics study.

  J Ethnopharmacol, Apr 2026

• [Plasma proteomics in age-related macular degeneration].

  Ophthalmologie, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.